Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
29 03 2019
Historique:
received: 25 10 2018
accepted: 07 03 2019
entrez: 31 3 2019
pubmed: 31 3 2019
medline: 6 5 2019
Statut: epublish

Résumé

Protein-protein interactions (PPIs) governing the recognition of substrates by E3 ubiquitin ligases are critical to cellular function. There is significant therapeutic potential in the development of small molecules that modulate these interactions; however, rational design of small molecule enhancers of PPIs remains elusive. Herein, we report the prospective identification and rational design of potent small molecules that enhance the interaction between an oncogenic transcription factor, β-Catenin, and its cognate E3 ligase, SCF

Identifiants

pubmed: 30926793
doi: 10.1038/s41467-019-09358-9
pii: 10.1038/s41467-019-09358-9
pmc: PMC6441019
doi:

Substances chimiques

Small Molecule Libraries 0
beta Catenin 0
beta-Transducin Repeat-Containing Proteins 0
Ubiquitin-Protein Ligases EC 2.3.2.27

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1402

Références

Science. 1997 Mar 21;275(5307):1790-2
pubmed: 9065403
Curr Opin Chem Biol. 2018 Jun;44:47-55
pubmed: 29885948
Genes Dev. 2002 May 1;16(9):1066-76
pubmed: 12000790
Nat Rev Drug Discov. 2017 Feb;16(2):101-114
pubmed: 27885283
Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):12-21
pubmed: 20057044
Cell. 2012 Jun 8;149(6):1245-56
pubmed: 22682247
Nat Chem Biol. 2017 Jun;13(6):675-680
pubmed: 28437394
Nature. 2001 Nov 15;414(6861):271-6
pubmed: 11713520
Methods Enzymol. 2005;398:125-42
pubmed: 16275325
Nat Rev Drug Discov. 2014 Jul;13(7):513-32
pubmed: 24981364
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
Annu Rev Biochem. 2009;78:399-434
pubmed: 19489725
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21
pubmed: 20124702
Front Biosci (Landmark Ed). 2012 Jun 01;17:2197-212
pubmed: 22652772
Mol Cell. 2003 Jun;11(6):1445-56
pubmed: 12820959
Nature. 2007 Apr 5;446(7136):640-5
pubmed: 17410169
Science. 2014 Jan 17;343(6168):305-9
pubmed: 24292623
Nature. 2014 Aug 7;512(7512):49-53
pubmed: 25043012
Cancer Res. 2001 Nov 15;61(22):8247-55
pubmed: 11719457
Nat Rev Cancer. 2014 Apr;14(4):233-47
pubmed: 24658274
Acta Crystallogr D Biol Crystallogr. 2009 Oct;65(Pt 10):1074-80
pubmed: 19770504
Science. 2017 Apr 28;356(6336):
pubmed: 28302793
Science. 2014 Jan 17;343(6168):301-5
pubmed: 24292625
Cell. 2013 Mar 14;152(6):1237-51
pubmed: 23498934
Br J Haematol. 2014 Mar;164(6):811-21
pubmed: 24328678
Mol Cell. 2004 Aug 27;15(4):511-21
pubmed: 15327768
Nature. 2016 Jun 22;535(7611):252-7
pubmed: 27338790
Cell. 2002 Mar 22;108(6):837-47
pubmed: 11955436
Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8554-9
pubmed: 11438690
Acta Crystallogr D Biol Crystallogr. 2012 Apr;68(Pt 4):352-67
pubmed: 22505256
Curr Opin Genet Dev. 2007 Feb;17(1):45-51
pubmed: 17208432
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):125-32
pubmed: 20124692
Nature. 2016 Apr 7;532(7597):127-30
pubmed: 26909574
Genes Dev. 2000 Aug 1;14(15):1837-51
pubmed: 10921899
Nat Struct Mol Biol. 2014 Sep;21(9):803-9
pubmed: 25108355
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
pubmed: 19461840
Science. 2015 Jun 19;348(6241):1376-81
pubmed: 25999370
Nat Rev Drug Discov. 2016 Aug;15(8):533-50
pubmed: 27050677
Expert Opin Drug Discov. 2017 Sep;12(9):925-940
pubmed: 28695752
Methods Enzymol. 2005;398:9-20
pubmed: 16275315
Cell. 2017 Jun 1;169(6):985-999
pubmed: 28575679
Cancer Res. 2003 Sep 1;63(17):5234-5
pubmed: 14500351

Auteurs

Kyle R Simonetta (KR)

Nurix Therapeutics, Inc., 1700 Owens Street, Suite 205, San Francisco, CA, 94158, USA. ksimonetta@nurix-inc.com.

Joshua Taygerly (J)

Nurix Therapeutics, Inc., 1700 Owens Street, Suite 205, San Francisco, CA, 94158, USA.

Kathleen Boyle (K)

Nurix Therapeutics, Inc., 1700 Owens Street, Suite 205, San Francisco, CA, 94158, USA.

Stephen E Basham (SE)

Nurix Therapeutics, Inc., 1700 Owens Street, Suite 205, San Francisco, CA, 94158, USA.

Chris Padovani (C)

Nurix Therapeutics, Inc., 1700 Owens Street, Suite 205, San Francisco, CA, 94158, USA.
Department of Molecular and Cell Biology, University of California, Berkeley, CA, 94720, USA.

Yan Lou (Y)

Nurix Therapeutics, Inc., 1700 Owens Street, Suite 205, San Francisco, CA, 94158, USA.
NiKang Therapeutics, Bldg. E500, 200 Powder Mill Road, Wilmington, DE, 19803, USA.

Thomas J Cummins (TJ)

Nurix Therapeutics, Inc., 1700 Owens Street, Suite 205, San Francisco, CA, 94158, USA.

Stephanie L Yung (SL)

Nurix Therapeutics, Inc., 1700 Owens Street, Suite 205, San Francisco, CA, 94158, USA.

Szerenke Kiss von Soly (SK)

Nurix Therapeutics, Inc., 1700 Owens Street, Suite 205, San Francisco, CA, 94158, USA.

Frank Kayser (F)

Nurix Therapeutics, Inc., 1700 Owens Street, Suite 205, San Francisco, CA, 94158, USA.
BioArdis, 7310 Miramar Road San Diego, San Diego, CA, 92126, USA.

John Kuriyan (J)

Department of Molecular and Cell Biology and Howard Hughes Medical Institute, University of California, Berkeley, CA, 94720, USA.

Michael Rape (M)

Department of Molecular and Cell Biology and Howard Hughes Medical Institute, University of California, Berkeley, CA, 94720, USA.

Mario Cardozo (M)

Nurix Therapeutics, Inc., 1700 Owens Street, Suite 205, San Francisco, CA, 94158, USA.

Mark A Gallop (MA)

Nurix Therapeutics, Inc., 1700 Owens Street, Suite 205, San Francisco, CA, 94158, USA.
5AM Ventures, 501 2nd Street, Suite 350, San Francisco, CA, 94107, USA.

Neil F Bence (NF)

Nurix Therapeutics, Inc., 1700 Owens Street, Suite 205, San Francisco, CA, 94158, USA.

Paul A Barsanti (PA)

Nurix Therapeutics, Inc., 1700 Owens Street, Suite 205, San Francisco, CA, 94158, USA.
5AM Ventures, 501 2nd Street, Suite 350, San Francisco, CA, 94107, USA.

Anjanabha Saha (A)

Nurix Therapeutics, Inc., 1700 Owens Street, Suite 205, San Francisco, CA, 94158, USA. sahaanjanabha@gmail.com.
5AM Ventures, 501 2nd Street, Suite 350, San Francisco, CA, 94107, USA. sahaanjanabha@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH